News

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.
Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.
Novo Nordisk, a leading global healthcare company, announced that the US Food and Drug Administration (FDA ... Wegovy oral formulation NDA will be in Q4 2025. Wegovy (semaglutide) injection 2.4 mg is ...
PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that the U.S. Food and Drug Administration ... Wegovy®Wegovy® (semaglutide) injection 2.4 mg is currently approved ...
accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity ...